Last Updated: May 2, 2026

CLINICAL TRIALS PROFILE FOR BACTRIM DS


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Bactrim Ds

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT03431168 ↗ A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV Active, not recruiting University of Alabama at Birmingham Phase 2 2018-03-07 More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes. The purpose of this randomized controlled trial is to evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to determine its efficacy and safety.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Bactrim Ds

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000936 ↗ A Study To Test An Anti-Rejection Therapy After Kidney Transplantation Terminated National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1999-11-01 Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed M.D. Anderson Cancer Center Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002850 ↗ Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed Eastern Cooperative Oncology Group Phase 3 1997-03-01 RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗ Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed National Cancer Institute (NCI) Phase 3 1997-03-01 RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗ Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed Gary Morrow Phase 3 1997-03-01 RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bactrim Ds

Condition Name

Condition Name for Bactrim Ds
Intervention Trials
Leukemia 6
Urinary Tract Infections 4
Abscess 4
Lymphoma 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bactrim Ds
Intervention Trials
Infections 15
Infection 14
Communicable Diseases 12
Leukemia 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bactrim Ds

Trials by Country

Trials by Country for Bactrim Ds
Location Trials
United States 120
France 4
Canada 3
Peru 3
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bactrim Ds
Location Trials
Texas 18
Ohio 9
Pennsylvania 8
New York 6
Michigan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bactrim Ds

Clinical Trial Phase

Clinical Trial Phase for Bactrim Ds
Clinical Trial Phase Trials
PHASE4 1
PHASE2 1
Phase 4 8
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bactrim Ds
Clinical Trial Phase Trials
Completed 35
Terminated 7
Not yet recruiting 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bactrim Ds

Sponsor Name

Sponsor Name for Bactrim Ds
Sponsor Trials
M.D. Anderson Cancer Center 11
National Institute of Allergy and Infectious Diseases (NIAID) 7
National Cancer Institute (NCI) 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bactrim Ds
Sponsor Trials
Other 115
Industry 17
NIH 17
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

BACTRIM DS (trimethoprim-sulfamethoxazole): Clinical Trials Update, Market Analysis and Projection

Last updated: April 24, 2026

What is BACTRIM DS and how is it used commercially?

BACTRIM DS is a fixed-dose combination (FDC) of trimethoprim and sulfamethoxazole formulated for treatment of bacterial infections. The product is widely marketed in multiple geographies as a generic-standard antibacterial therapy rather than as a proprietary branded, patent-protected development program.

Clinical development posture

  • No active, sponsor-sponsored “new drug” pivotal phase program is required for an already marketed, off-patent combination product.
  • Competitive dynamics are dominated by formulation/labeling variations, country-level registrations, pricing, and generic substitution.

Implication for “clinical trials update”

  • For BACTRIM DS specifically, meaningful “pipeline” signal generally appears as:
    • Post-marketing safety studies (pharmacovigilance analyses, observational studies)
    • Antimicrobial stewardship and resistance surveillance
    • Bioequivalence and formulation quality work for generic entrants (jurisdiction-specific)

What do the public clinical-trials signals indicate (status snapshot)?

Because BACTRIM DS is an established FDC, public clinical-trials visibility typically concentrates in:

  • Observational cohort studies on TMP-SMX effectiveness/safety in specific populations (pediatrics, renal impairment, HIV-associated infections, skin and soft tissue infections, UTI subsets).
  • Comparative effectiveness against other antibiotics for targeted indications.
  • Susceptibility and resistance surveillance that informs guideline use.

Where to verify current trial activity

  • ClinicalTrials.gov: Use the query string “trimethoprim sulfamethoxazole” plus condition filters tied to labeled indications.
  • EU Clinical Trials Register: Search the same active ingredient/combination terms and condition names.

Market-impacting takeaway from the typical structure

  • For BACTRIM DS, trial volume does not function like a proprietary pipeline. Instead, ongoing studies mostly support label maintenance and prescribing evidence rather than creating new exclusivity.

Which regulatory and prescribing anchors shape BACTRIM DS demand?

Demand is anchored to how clinicians use TMP-SMX across common infection categories and how regulators frame safety constraints.

Key guideline and safety anchors that influence utilization

  • TMP-SMX use depends on local resistance rates and tolerability.
  • Safety concerns that show up repeatedly in practice (and in prescribing constraints) include:
    • Hypersensitivity reactions
    • Hematologic effects
    • Renal and electrolyte effects (notably hyperkalemia risk in susceptible patients)
    • Severe cutaneous adverse reactions (rare but clinically important)

Clinical practice drivers

  • TMP-SMX is used in:
    • Skin and soft tissue infections (where susceptible)
    • Urinary tract infection in selected contexts
    • Pneumocystis jirovecii prophylaxis and treatment in HIV and other immunocompromised settings (where it is guideline-supported)
    • Other infection indications that remain label- and country-dependent

What is the competitive landscape for BACTRIM DS?

BACTRIM DS operates in a high-generic, low-differentiation arena.

Competitive vectors

  • Generic TMP-SMX tablets and suspensions compete directly.
  • Differentiation is typically limited to:
    • Dosage form and strength presentation
    • Excipient profile
    • Labeling language and local indication scope
  • Procurement is often price-driven via:
    • Hospital formularies
    • National tender pricing
    • Bulk purchasing and substitution rules

Market consequence

  • Any market projection for BACTRIM DS should be modeled as:
    • Volume growth linked to infection incidence and guideline use
    • Price erosion driven by generic competition
    • Periodic demand spikes driven by outbreak patterns or resistance shifts

What is the market outlook for systemic TMP-SMX (BACTRIM DS segment)?

Global market direction

The systemic antibacterial space shows steady demand for established agents, but TMP-SMX is pressured by:

  • Generic price competition
  • Shifts in guideline antibiotic selection based on local resistance and stewardship targets
  • Safety-led prescribing caution in comorbid populations

Segment-level demand drivers

  • Companion prophylaxis use cases (notably immunocompromised populations) support baseline demand in many countries.
  • Community infections influence seasonal and regional demand variation.
  • Resistance surveillance can move clinicians toward or away from TMP-SMX by locale.

Projection framework (practical for investment and R&D)

For an FDC like BACTRIM DS, market projection is best treated as:

  • TAM: infections treated with TMP-SMX per guideline scope
  • SAM: countries/segments where oral TMP-SMX remains guideline-supported and commercially available at scale
  • SOM: brand/generic share based on tender access and formulary status

How do you project BACTRIM DS without a proprietary pipeline?

A credible projection uses macro plus channel math rather than trial-driven catalysts.

Projection model inputs

  • Baseline prescriptions for TMP-SMX (proxy: total TMP-SMX dispensed units)
  • Price index for generics vs. branded
  • Formulary access: hospital listing status and substitution frequency
  • Regulatory and safety updates affecting label wording and prescriber behavior

Expected directionality

  • Revenue: tends to move slowly or decline in nominal terms due to pricing compression.
  • Units: tends to hold up better than revenue due to persistent guideline use, with sensitivity to resistance trends and stewardship.

What are actionable R&D and business implications from this clinical profile?

With BACTRIM DS as an established FDC, the highest ROI initiatives tend to be operational rather than discovery-led.

Most actionable initiatives

  • Bioequivalence and formulation optimization for generic entrants (jurisdiction-specific compliance)
  • Evidence generation for subpopulations that influence prescribing:
    • renal impairment handling
    • allergy-risk mitigation
    • adherence and tolerability optimization (where allowed)
  • Real-world outcomes: linking stewardship targets to outcomes and adverse event rates

Least aligned initiatives

  • Novel efficacy trials aimed at “new exclusivity” are typically not rational because the molecule is already standard-of-care and competitive barriers are low.

Market projections: what scenarios matter most?

Because the molecule is off-patent in most key markets, the projection sensitivity typically sits in:

  1. Pricing compression rate
  2. Local resistance regime (drives guideline positioning)
  3. Safety signal intensity in public and clinical communications
  4. Channel access (formularies, tenders, national reimbursement lists)

Scenario design

  • Base case: stable units, modest revenue growth or flat nominal revenue depending on price trajectory
  • Downside: units soften due to stewardship or resistance shifts; revenue falls faster with accelerated price erosion
  • Upside: units expand in specific communities or immunocompromised prophylaxis coverage increases; revenue stabilizes if tender pricing holds

What do investors and developers track for BACTRIM DS specifically?

Channel and pricing metrics

  • Generic tender prices for TMP-SMX oral solids
  • Reimbursement status and substitution rules
  • Hospital formularies in key payer systems

Clinical utilization metrics

  • Treatment and prophylaxis uptake rates
  • Adverse event reporting trends (signal strengthening reduces prescribing)

Regulatory and label metrics

  • Any label tightening on renal/electrolyte safety language
  • Country-by-country indication changes

Key Takeaways

  • BACTRIM DS is an established TMP-SMX FDC in a high-generic, low-differentiation market. The clinical trial landscape is more consistent with post-marketing evidence and real-world studies than with a proprietary, trial-driven pipeline.
  • Market performance is driven by guideline use, local resistance, and stewardship, with revenue heavily exposed to generic price erosion.
  • For planning and investment, the most usable projection approach is channel-based forecasting (units and tender pricing) rather than assuming trial catalysts.
  • R&D that fits the business reality focuses on formulation/registration compliance and subpopulation evidence that changes prescribing behavior.

FAQs

1) Does BACTRIM DS have active phase 3 development that drives exclusivity?

No. BACTRIM DS functions as an established, off-patent standard therapy; clinical activity is typically observational, post-marketing, or generic compliance rather than exclusivity-forming late-stage development.

2) What most affects BACTRIM DS demand in practice?

Local antimicrobial resistance patterns, stewardship guidance, and safety tolerability in real-world populations.

3) How should revenue be forecast for BACTRIM DS?

Model revenue using unit stability/changes plus ongoing generic price erosion. Base case assumptions should reflect tender and reimbursement dynamics.

4) What is the most likely “upside” catalyst for the segment?

Improved channel access (formularies, tender wins) and stabilization of generic pricing, not new efficacy breakthroughs.

5) What is the most likely “downside” risk to the segment?

Stewardship shifts away from TMP-SMX due to resistance or safety communications that reduce prescribing.


References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] World Health Organization. WHO Model Formulary / antimicrobial guidance resources (background on antimicrobial use principles). https://www.who.int/
[3] European Medicines Agency. Clinical trial and medicine information resources. https://www.ema.europa.eu/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.